Regenicin Inc (RGIN) Annual Balance Sheets

Annual · GAAP · USD millions
Access RGIN quarterly Balance Sheets →
Examining balance sheet movements between Regenicin Inc and Sep 30 2018 reveals how Sep 30 2022 adjusts its asset composition and liability profile.
Annual Report, GAAP in USD millions
ITEM
(Sep 30 2022)
(Sep 30 2021) (Sep 30 2020) (Sep 30 2019) (Sep 30 2018)
Assets
Cash & cash equivalent0.01
Cash & Short-term Investments0.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.00
Total Current Assets0.02
Other Assets, Noncurrent0.00
Common Stock Receivable0.00
Total Assets0.02
Liabilities
Accounts Payable, Current AC0.10
Accrued Liabilities, Current4.87
Short-term Debt0.19
Other Liabilities, Current0.46
Total Current Liabilities5.61
Long-term debt0.12
Total Long-term Debt0.12
Other liabilities, Noncurrent0.00
Loans Payable Related Parties0.00
Total Liabilities5.73
Stockholders' Equity
Series A Preferred Stock Value0.00
Treasury Stock-
Common Stock Value0.16
Treasury Stock Value0.00
Additional Paid In Capital Common Stock10.21
Retained Earnings / Accumulated Deficit-15.96
Other Equity0.00
Common Stockholder's Equity-5.60
Total Stockholder's Equity-5.60
Liabilities & Stockholder's Equity0.02
4 historic quarters locked

Sign in to unlock the full Regenicin Inc balance sheet history.

About Regenicin Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001662252-23-000017

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License